Six physicians at UCLA’s Geffen School of Medicine authored the study and stated that six therapies for heart failure could have prevented that total death figure. The six therapies include angiotensin-converting enzyme inhibitor/angiotensin receptor antagonist, β-blockers, aldosterone antagonists, hydralazine/isorbide dinitrat, implantable cardioverter-defibrillators and cardiac resynchronization therapy.
The research also showed that nearly 2.7 million heart failure patients were eligible for those therapies but did not receive treatment.
Related Articles on Heart Specialties:
Essentia Program Reduces Readmission Rates, Costs for Heart Failure Patients
Study: Tai Chi May Help Improve Quality of Life for Systolic Heart Failure Patients
New Jersey Pilot Program Monitors Heart Patients From Home, Aims to Reduce Hospital Visits
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
